Q2 EPS Estimate for Bausch Health Cos Decreased by Analyst

Bausch Health Cos Inc. (NYSE:BHC) – Analysts at Zacks Research decreased their Q2 2027 earnings per share estimates for shares of Bausch Health Cos in a research report issued on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.89 for the quarter, down from their previous forecast of $0.96. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2028 earnings at $3.36 EPS.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). Bausch Health Cos had a return on equity of 875.00% and a net margin of 1.53%.The company had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.71 billion.

Several other equities research analysts have also recently commented on the stock. Raymond James Financial reiterated a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Truist Financial raised their price objective on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Barclays lowered their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Finally, Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $8.33.

Bausch Health Cos Trading Down 1.7%

Shares of Bausch Health Cos stock opened at $4.97 on Friday. The business has a fifty day simple moving average of $6.20 and a 200-day simple moving average of $6.53. Bausch Health Cos has a fifty-two week low of $4.25 and a fifty-two week high of $8.69. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 11.82 and a beta of 0.37. The company has a quick ratio of 1.08, a current ratio of 1.47 and a debt-to-equity ratio of 54.68.

Institutional Investors Weigh In On Bausch Health Cos

Several hedge funds have recently modified their holdings of the stock. Tidal Investments LLC increased its stake in Bausch Health Cos by 2.6% in the 2nd quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock worth $334,000 after purchasing an additional 1,276 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after buying an additional 1,812 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock worth $690,000 after buying an additional 2,552 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the period. Finally, Squarepoint Ops LLC increased its position in shares of Bausch Health Cos by 4.6% in the fourth quarter. Squarepoint Ops LLC now owns 78,715 shares of the company’s stock worth $547,000 after acquiring an additional 3,495 shares in the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bausch Health Cos

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks bumped some near‑term/near‑term‑adjacent forecasts — including FY‑2026 (to $3.92 EPS), Q4‑2026 (to $1.10), Q1‑2027 (to $0.82) and Q3‑2027 (to $1.12) — suggesting parts of the company’s near‑term earnings outlook improved. Zacks revisions (summary)
• Neutral Sentiment: Zacks published an FY‑2028 estimate ($3.36 EPS) which provides a longer‑horizon view but is farther out and less likely to move the stock materially in the short term. FY‑2028 estimate
• Negative Sentiment: Zacks trimmed a number of core near‑term forecasts: Q2‑2027 EPS was cut notably (from $0.96 to $0.89) and Zacks reduced its FY‑2027 outlook (to $3.79 from $3.85), along with cuts to several quarterly estimates — a driver of downward earnings expectations and selling pressure. Zacks cuts (summary)
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud; while that probe targets BLCO, market participants may view it as a reputational/legal overhang for companies carrying the Bausch name or related assets, increasing risk sentiment. Bausch + Lomb investigated (GlobeNewswire)

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.